Drugs / NBQ72S
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06810804 | Apr 2025 → Aug 2026 overdue | breast cancer | Nantong Bencao Quadriga Medical Technology Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NBQ72S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06810804 ↗ |
| Route | Intravenous | “receive intravenous infusion of NBQ72S” NCT06810804 ↗ |